One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   North America Human Insulin Drugs Market

[ 英語タイトル ] North America Human Insulin Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0087983
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 85
Category : Healthcare and Pharmaceuticals
Study Area : North America
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Novo Nordisk A/S
- Sanofi S.A.
- Eli Lilly and Company
- Biocon Limited
- Pfizer Inc.
- Wockhardt
- Julphar
- Exir
- Sedico

[Report Description]

The North American human insulin drugs market is expected to register a CAGR of 4.41% during the forecast period of 2020 - 2025, and the market is estimated to reach a value of USD 12 billion by 2025. North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Key Market Trends

The United States Dominates the Market

Among the North American countries, the United States dominates around 94% of the total North America Human Insulin Drugs Market. This is mainly due to the high diabetes prevalence in the country. The United States records the highest healthcare expenditure globally, and it also has a higher adoption of advanced therapeutics. The market size of the insulin market in 2017 was USD 10.6 billion, and the market is expected to record a CAGR of 4.29% during the forecast period (2020 - 2025). Moreover, the United States accounts for the highest sales of the long-acting insulin, Lantus, across the North America Region. The majority of diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market.

Humalog holds Highest Market Share in 2019.

Humalog occupied the largest market share in 2019. However, the product is expected to decrease during the forecast period, due to similar insulin glargine present in the market, like FIASP and Admelog. Admelog is proven to lower A1C similar to Humalog. Admelog is available in the Admelog SoloStar pen or a vial and can be used in a pump. In March 2019, Eli Lilly launched the authorized generic of its insulin lispro injection (Humalog) in the United States. The new generic Humalog has a list price 50% lower than the Humalog list price existing in the market.

Competitive Landscape

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Insulin (Value and Volume 2012-2025)
5.1.1.1 Basal or Long-acting Insulin
5.1.1.1.1 Lantus (Insulin Glargine)
5.1.1.1.2 Levemir (Insulin Detemir)
5.1.1.1.3 Toujeo (Insulin Glargine)
5.1.1.1.4 Tresiba (Insulin Degludec)
5.1.1.1.5 Basaglar (Insulin Glargine)
5.1.1.2 Bolus or Fast-acting Insulin
5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.1.2.2 Humalog (Insulin Lispro)
5.1.1.2.3 Apidra (Insulin Glulisine)
5.1.1.2.4 FIASP (Insulin aspart)
5.1.1.2.5 Admelog (Insulin lispro)
5.1.1.3 Traditional Human Insulin
5.1.1.3.1 Novolin/Actrapid/Insulatard
5.1.1.3.2 Humulin
5.1.1.3.3 Insuman
5.1.1.4 Combination Insulin
5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
5.1.1.5 Biosimilar Insulin
5.1.1.5.1 Insulin Glargine Biosimilars
5.1.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2025)
5.2.1.1.1 Basal or Long-acting Insulin
5.2.1.1.2 Bolus or Fast-acting Insulin
5.2.1.1.3 Traditional Human Insulin
5.2.1.1.4 Combination Insulin
5.2.1.1.5 Biosimilar Insulin
5.2.1.2 Canada (Value and Volume 2012-2025)
5.2.1.2.1 Basal or Long-acting Insulin
5.2.1.2.2 Bolus or Fast-acting Insulin
5.2.1.2.3 Traditional Human Insulin
5.2.1.2.4 Combination Insulin
5.2.1.2.5 Biosimilar Insulin
5.2.1.3 Rest of North America (Value and Volume 2012-2025)
5.2.1.3.1 Basal or Long-acting Insulin
5.2.1.3.2 Bolus or Fast-acting Insulin
5.2.1.3.3 Traditional Human Insulin
5.2.1.3.4 Combination Insulin
5.2.1.3.5 Biosimilar Insulin

6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2025)
6.2 Type 2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.1.1 Overview
7.1.1.2 Products and Strategies
7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.1.4 Ratio Analysis (5 Years)
7.1.1.5 Strength and Stability Analysis (5 Years)
7.1.1.6 Recent Developments
7.1.2 Sanofi S.A.
7.1.2.1 Overview
7.1.2.2 Products and Strategies
7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.2.4 Ratio Analysis (5 Years)
7.1.2.5 Strength and Stability Analysis (5 Years)
7.1.2.6 Recent Developments
7.1.3 Eli Lilly and Company
7.1.3.1 Overview
7.1.3.2 Products and Strategies
7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.3.4 Ratio Analysis (5 Years)
7.1.3.5 Strength and Stability Analysis (5 Years)
7.1.3.6 Recent Developments
7.1.4 Biocon Limited
7.1.4.1 Overview
7.1.4.2 Products and Strategies
7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.4.4 Ratio Analysis (5 Years)
7.1.4.5 Strength and Stability Analysis (5 Years)
7.1.4.6 Recent Developments
7.1.5 Pfizer Inc.
7.1.5.1 Overview
7.1.5.2 Products and Strategies
7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.5.4 Ratio Analysis (5 Years)
7.1.5.5 Strength and Stability Analysis (5 Years)
7.1.5.6 Recent Developments
7.1.6 Wockhardt
7.1.6.1 Overview
7.1.6.2 Products and Strategies
7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.6.4 Ratio Analysis (5 Years)
7.1.6.5 Strength and Stability Analysis (5 Years)
7.1.6.6 Recent Developments
7.1.7 Julphar
7.1.7.1 Overview
7.1.7.2 Products and Strategies
7.1.7.3 Recent Developments
7.1.8 Exir
7.1.8.1 Overview
7.1.8.2 Products and Strategies
7.1.8.3 Recent Developments
7.1.9 Sedico
7.1.9.1 Overview
7.1.9.2 Products and Strategies
7.1.9.3 Recent Developments
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi S.A.
7.2.3 Eli Lilly and Company
7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+